Related Experiment Video
Updated: Jul 16, 2025
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Identifying Luteolin as a Potential Drug for Treating Lung Adenocarcinoma with COVID-19 Affection based on
1Department of thoracic surgery, Tongji Hospital, Wuhan, 430000, China.
Background:
Lung adenocarcinoma (LUAD) is a major type of lung cancer worldwide, and under the pandemic coronavirus disease 2019 (COVID-19), its cancer burden is enlarged. This study aimed to explore potential drug targets and potential drugs for developing effective treatments for patients with both lung cancer and COVID-19.
Methods:
The interaction network of molecule compounds-target genes was constructed based on Traditional Chinese Medicines (TCMs) and gene expression data from public databases. The potential effectiveness of drugs was analyzed by molecular docking and molecular dynamics simulation. Western blot, transfection assay, Immunohistochemistry (IHC) staining, and flow cytometry were performed to investigate the function of HSP90AA1 in LUAD cells.
Result:
Eight target genes (GSK3B, HMOX1, HSP90AA1, ICAM1, MAPK1, PLAU, RELA and TNFSF15.) were identified, and two of them (HSP90AA1 and RELA) were significantly associated with LUAD prognosis. Luteolin was discovered to bind with HSP90AA1. Moreover, in vitro cell experiments demonstrated that HSP90AA1 had higher expression in A549 cells, promoted cell viability and suppressed apoptosis in A549 cells and H1299 cells.
Conclusion:
HSP90AA1 was a target gene for further designing effective drugs for LUAD patients. Luteolin was a potential drug for treating patients with both LUAD and COVID-19.
Insights
Heat shock protein 90 kDa alpha class A member 1 (HSP90AA1) is a potential drug target for lung adenocarcinoma (LUAD). Luteolin shows promise as a treatment for patients with both LUAD and coronavirus disease 2019 (COVID-19).
Area of Science:
- Oncology
- Virology
- Pharmacology
Background:
- Lung adenocarcinoma (LUAD) presents a significant global health challenge, exacerbated by the coronavirus disease 2019 (COVID-19) pandemic.
- The co-occurrence of LUAD and COVID-19 necessitates the identification of novel therapeutic strategies.
- This research addresses the urgent need for effective treatments for patients affected by both conditions.
Purpose of the Study:
- To identify potential drug targets for lung adenocarcinoma.
- To discover potential therapeutic agents for treating patients with concurrent LUAD and COVID-19.
- To investigate the role of HSP90AA1 in LUAD progression.
Main Methods:
- Construction of a molecule compounds-target genes interaction network using Traditional Chinese Medicines (TCMs) and gene expression data.
- Analysis of drug efficacy through molecular docking and molecular dynamics simulations.
- Experimental validation using Western blot, transfection assays, Immunohistochemistry (IHC), and flow cytometry to assess HSP90AA1 function.
Main Results:
- Eight key target genes were identified, with HSP90AA1 and RELA significantly linked to LUAD prognosis.
- Luteolin demonstrated binding affinity to HSP90AA1.
- In vitro studies confirmed elevated HSP90AA1 expression in LUAD cells, promoting cell viability and inhibiting apoptosis.
Conclusions:
- HSP90AA1 emerges as a promising therapeutic target for LUAD drug development.
- Luteolin is identified as a potential therapeutic candidate for patients with both LUAD and COVID-19.
- Further research into HSP90AA1 and luteolin could lead to novel treatment strategies.
